Given that colorectal tumors are more addicted to EGFR signaling for growth and survival than other types of malignancies, the conclusion that EGFR feedback signaling confers partial resistance to KRASG12C and KRASG12D inhibition therapy is likely a universal mechanism for other KRAS variant oncoprotein inhibitors in CRC. Here, KRAS is linked to colorectal neoplasm.